The PREDICT (Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted Therapeutics) Approach to Biomarker Discovery in Renal Cell Carcinoma

Trial Profile

The PREDICT (Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted Therapeutics) Approach to Biomarker Discovery in Renal Cell Carcinoma

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Apr 2012

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms S-PREDICT
  • Most Recent Events

    • 30 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top